Wall Street analysts expect Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to post ($1.22) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.80). Ultragenyx Pharmaceutical reported earnings of ($2.04) per share during the same quarter last year, which would suggest a positive year over year growth rate of 40.2%. The business is scheduled to issue its next earnings results on Wednesday, May 5th.
On average, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($4.81) per share for the current financial year, with EPS estimates ranging from ($5.69) to ($3.88). For the next financial year, analysts forecast that the firm will report earnings of ($4.21) per share, with EPS estimates ranging from ($6.04) to ($1.22). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Ultragenyx Pharmaceutical.
Several equities analysts have recently issued reports on the company. Piper Sandler boosted their target price on Ultragenyx Pharmaceutical from $165.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, February 12th. TheStreet upgraded shares of Ultragenyx Pharmaceutical from a “d” rating to a “c-” rating in a report on Tuesday, February 16th. JPMorgan Chase & Co. cut shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $165.00 target price for the company. in a research report on Friday, February 12th. Robert W. Baird boosted their price target on shares of Ultragenyx Pharmaceutical from $110.00 to $165.00 and gave the company an “outperform” rating in a research report on Monday, January 11th. Finally, Stifel Nicolaus began coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, March 1st. They issued a “buy” rating and a $179.00 price objective for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. Ultragenyx Pharmaceutical has a consensus rating of “Hold” and an average price target of $132.50.
Several institutional investors have recently bought and sold shares of RARE. AGF Investments LLC bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at $25,000. Point72 Hong Kong Ltd bought a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $57,000. Captrust Financial Advisors bought a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at about $75,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $112,000. Finally, Harvest Fund Management Co. Ltd grew its stake in shares of Ultragenyx Pharmaceutical by 15.9% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 888 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 122 shares during the period.
NASDAQ RARE opened at $105.27 on Thursday. Ultragenyx Pharmaceutical has a 1 year low of $50.22 and a 1 year high of $179.65. The stock has a market capitalization of $7.05 billion, a PE ratio of -23.98 and a beta of 2.19. The business’s 50-day moving average is $125.80 and its 200 day moving average is $125.00.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders.
Recommended Story: How is net asset value different from market price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.